Stan Berenshteyn

Q: What is Stan Berenshteyn's success rate?

Stan Berenshteyn currently has a success rate of 94.63519734126623.

Q: What is the average return of Stan Berenshteyn's calls?

Their stock ratings have generated an average return of 4.927041224994587.

Wells Fargo | Healthcare

Stan Berenshteyn is an analyst from Wells Fargo specializing in the Healthcare sector. Ranked #1412 out of 4525 analysts, they have issued 22 stock ratings with a success rate of 94.64% and an average return of 4.93%.

Stan Berenshteyn has a well-established track record, with 22 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 94.64% and an average return of 4.93%, underscoring their expertise and ability to identify winning opportunities for investors.

#1412

Out of 4525

Total Ratings

+94.64%

Success Rate

+4.93%

Average Return

Recent Ratings Analysis

DOCS

Buy

Jan 20, 2026

Target

$55.00

Current

$41.10

Performance

0.00%

Stan Berenshteyn rated DOCS as Overweight on Jan 20, 2026, setting a price target of 55. Shares have remained stable near 41.1, leaving the 55 target still in play.

CTEV

Hold

Jan 09, 2026

Target

$33.00

Current

$28.49

Performance

-1.55%

On Jan 09, 2026, CTEV was given a Equal-Weight rating by Stan Berenshteyn, with a target price of 33. Market indecision, reflected in sideways trading near 28.49, supported the cautious call.

WAY

Buy

Jan 09, 2026

Target

$41.00

Current

$29.74

Performance

-13.80%

WAY received a Overweight rating from Stan Berenshteyn on Jan 09, 2026, aiming for 41. The rating hasn’t played out as hoped, with the stock trading 13.80% below expectations.

PHR

Buy

Jan 09, 2026

Target

$30.00

Current

$15.73

Performance

-8.71%

On Jan 09, 2026, Stan Berenshteyn published a Overweight outlook on PHR, with a target of 30. Market action contradicted the Buy thesis, as shares slipped to 15.73.

OMDA

Hold

Jan 09, 2026

Target

$17.00

Current

$15.74

Performance

2.14%

Stan Berenshteyn on Jan 09, 2026 assigned OMDA a Equal-Weight rating, with a price target of 17. The Hold stance reflected consolidation, as shares held near 15.74.

HNGE

Buy

Jan 09, 2026

Target

$68.00

Current

$41.62

Performance

-13.15%

On Jan 09, 2026, Stan Berenshteyn reaffirmed HNGE with a Overweight rating, targeting 68. Shares slid 13.15% despite the recommendation, highlighting downside risks.

OMCL

Buy

Jan 05, 2026

Target

$52.00

Current

$49.06

Performance

4.54%

OMCL was rated Overweight by Stan Berenshteyn on Jan 05, 2026, with a price objective of 52. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

VEEV

Buy

Nov 25, 2025

Target

$341.00

Current

$216.26

Performance

-9.87%

On Nov 25, 2025, Stan Berenshteyn initiated coverage on VEEV with a Overweight rating and target of 341. The Buy call has yet to be validated as shares remain 124.74 away from the target.

HCAT

Buy

Nov 11, 2025

Target

$5.00

Current

$2.21

Performance

-17.84%

Stan Berenshteyn issued a Overweight recommendation for HCAT on Nov 11, 2025, price target set at 5. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

AMWL

Buy

Nov 05, 2025

Target

$9.00

Current

$4.60

Performance

0.66%

On Nov 05, 2025, AMWL was evaluated by Stan Berenshteyn, who gave a Overweight rating and target of 9. So far, the Buy call awaits clearer momentum, with shares flat at 4.6.

GDRX

Buy

Feb 28, 2025

Target

$8.00

Current

$2.60

Performance

-47.79%

Stan Berenshteyn rated GDRX as Overweight on Feb 28, 2025, setting a price target of 8. The stock has underperformed, dropping 47.79% despite the bullish target of 8.

HQY

Buy

Feb 26, 2025

Target

$125.00

Current

$84.00

Performance

-20.46%

On Feb 26, 2025, HQY was given a Overweight rating by Stan Berenshteyn, with a target price of 125. Despite the Buy call, shares fell from 84 to 84, challenging the optimistic stance.

ACCD

Hold

Oct 11, 2024

Target

$6.00

Current

$7.02

Performance

85.22%

ACCD received a Equal-Weight rating from Stan Berenshteyn on Oct 11, 2024, aiming for 6. Investors saw gains of 85.22% that the cautious stance didn’t fully capture.

Frequency Asked Questions

Who is Stan Berenshteyn?

Stan Berenshteyn is an analyst from Wells Fargo specializing in the Healthcare sector.

What is Stan Berenshteyn's success rate?

Stan Berenshteyn currently has a success rate of +94.64%.

How many ratings has Stan Berenshteyn issued?

Stan Berenshteyn has issued 22 stock ratings so far.

What is the average return of Stan Berenshteyn's calls?

Their stock ratings have generated an average return of +4.93%.

What is Stan Berenshteyn's ranking?

Stan Berenshteyn is ranked #1412 out of 4525 analysts.

What types of ratings does Stan Berenshteyn give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Stan Berenshteyn?

You can follow Stan Berenshteyn by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Stan Berenshteyn?

Their latest rating was a Buy on DOCS issued on 2026-01-20.